In the latest market close, Eli Lilly (LLY) reached $887.16, with a +0.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.Shares of the drugmaker have depreciated by 2.98% over the course of the past month, outperforming the Medical sector's loss of 4.05% and lagging the S&P 500's gain of 3.15%.The upcoming earnings release of Eli Lilly will be of great interest to investors. It is anticipated ...

Thursday, The FDA determined the shortage of Eli Lilly And Co’s LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs.The FDA noted that Novo Nordisk A/S‘ NVO semaglutide (Wegovy, Ozempic) is still in shortage.Despite semaglutide being the active ing ...

Eli Lilly and Company (LLY) announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable the development of new methods for making its drugs and also scale up the supply of medicines for clinical trials for Lilly's growing pipeline. This one-of-a-kind facility, which combines research and manufacturing in a single location, will open in 2027. The Medicine Foundry, which is expected to creat ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Eli Lilly (LLY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Eli Lilly is a member of our Medical group, which includes 1025 different companie ...

The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages. The initial shortage led the FDA to permit pharmacies to sell less-tested generic versions. Eli Lilly has been increasing investments to boost medication supply, including constructing a ne ...

The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.Mounjaro, which is primarily used for diabetes treatment, and Zepbound, used for weight control, had been listed on the FDA's shortage list since late 2022 and Apri ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of i ...

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020 INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced man ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned -8.6% over the past month versus the Zacks S&P 500 composite's +2.1% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has lost 5.5% over this period. Now the key question is: Where could the stock be headed in the near term?Although me ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.With all the focus on Eli Lilly's (NYSE: LLY ) obesity business, the rec ...